About Rodeo Therapeutics
Rodeo Therapeutics is a company based in Seattle (United States) founded in 2017 by Stanton Gerson and Sanford Markowitz was acquired by Amgen in March 2021.. Rodeo Therapeutics has raised $14.85 million across 2 funding rounds from investors including Amgen, AbbVie and Lilly. Rodeo Therapeutics operates in a competitive market with competitors including Aclaris Therapeutics, Protagonist Therapeutics, OMass Therapeutics, Enterome and CytoKi Pharma, among others.
- Headquarter Seattle, United States
- Founders Stanton Gerson, Sanford Markowitz
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Software Development Team
208 people
Leadership Team
193 people
Sales and Marketing
82 people
Data Analysis and Operations Team
73 people
Senior Team
66 people
Operations Team
64 people
Product Management Team
55 people
Scientific Team
34 people
Unlock access to complete
Funding Insights of Rodeo Therapeutics
Rodeo Therapeutics has successfully raised a total of $14.85M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $8.95 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $8.9M
-
First Round
First Round
(02 Aug 2017)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2020 | Amount | Series A - Rodeo Therapeutics | Valuation |
investors |
|
| Aug, 2017 | Amount | Series A - Rodeo Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Rodeo Therapeutics
Rodeo Therapeutics has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Amgen, AbbVie and Lilly. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early stage investments focused VC firm
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location | |
|
Venture capital services are offered for early-stage biotech companies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Rodeo Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Rodeo Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Rodeo Therapeutics Comparisons
Competitors of Rodeo Therapeutics
Rodeo Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Protagonist Therapeutics, OMass Therapeutics, Enterome and CytoKi Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Oral peptide therapeutics are developed for gastrointestinal diseases.
|
|
| domain | founded_year | HQ Location |
Proprietary mass spectrometry technologies are developed for protein assembly analysis.
|
|
| domain | founded_year | HQ Location |
Developer of immunomodulators for cancer and auto-immune diseases
|
|
| domain | founded_year | HQ Location |
Therapeutics for epithelial-based diseases are developed and targeted.
|
|
| domain | founded_year | HQ Location |
Biotherapeutics for auto-immune disorders and type-1 diabetes are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Rodeo Therapeutics
Frequently Asked Questions about Rodeo Therapeutics
When was Rodeo Therapeutics founded?
Rodeo Therapeutics was founded in 2017.
Where is Rodeo Therapeutics located?
Rodeo Therapeutics is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Is Rodeo Therapeutics a funded company?
Rodeo Therapeutics is a funded company, having raised a total of $14.85M across 2 funding rounds to date. The company's 1st funding round was a Series A of $5.9M, raised on Aug 02, 2017.
What does Rodeo Therapeutics do?
Rodeo Therapeutics, a preclinical-stage biotech company, is focused on first in class small molecule modulators of prostaglandin biology for enhancing tissue repair and regeneration. The company is developing 15-PGDH (prostaglandin-degrading enzyme) inhibitors for the treatment of inflammatory bowel disease and promoting blood cell reconstitution following the bone marrow transplant (preclinical). Preclinical studies published in Science have shown that increasing PGE2 through inhibition of a prostaglandin-degrading enzyme (15-PGDH) accelerates hematopoietic stem cell reconstitution following bone marrow transplant, protects against colitis and promotes liver regeneration in a variety of animal models.
Who are the top competitors of Rodeo Therapeutics?
Rodeo Therapeutics's top competitors include Aclaris Therapeutics, Protagonist Therapeutics and Samsung Bioepis.
Who are Rodeo Therapeutics's investors?
Rodeo Therapeutics has 10 investors. Key investors include Amgen, AbbVie, Lilly, WuXi AppTec, and Arch Venture Partners.